Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
[Delayed]Notice of Recognition of Gain on Deferred Income Taxes
JCR Pharmaceuticals Announces Chairman and President Transition as of April 1, 2026
FY2024 Results Briefing Session Material
Financial Summary Consolidated Financial Results for the Year ended March 31, 2025 (FY2024) (Japanese standard)
JCR Pharmaceuticals Announces New Corporate Philosophy and Core Values
Notice of Distribution of Retained Earnings
JCR Pharmaceuticals to Present at the American Society of Gene and Cell Therapy 28th Annual Meeting
Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by the U.S. FDA
Notice of Election of Candidate for New Audit & Supervisory Board Members
JCR Revises Full-Year Consolidated Forecast for FY2024
Change in Duties of Corporate Officers, Organizational and Personnel Changes
Notice Concerning the Start of Construction of a New Drug Product Plant
JCR Pharmaceuticals Proudly Supports Rare Disease Day 2025
Notice of Partial Correction to “FY2024 Third Quarter Consolidated Financial Results Conference Call Material”
JCR Pharmaceuticals’ Research Presentations at WORLDSymposium 2025 Showcase Research from Its Investigational Treatments for LSDs
Summary of Financial Results for the third quarter 2025
Financial Summary Consolidated Financial Results for the Nine Months ended December 31, 2024 (FY2024) (Japanese standard)
Revision of Consolidated Financial Forecasts for Fiscal Year Ended March 31, 2025
FY2024 Third Quarter Consolidated Financial Results Conference Call
JCR Pharmaceuticals to Present at the 21st Annual WORLDSymposiumTM 2025